ePAT and PainChek continue to achieve commercial milestones
Filed with ASX · · 2 pages · English
Earlier from PainChek
- Placement to raise $3.75 million
- Core strategic agreement with Dementia Support Australia
- ePAT Clinical Study Published in Alzheimers Disease Journal
- nViso agrees perpetual global license, takes strategic stake
- ePAT Pain Assessment App Secures Regulatory Clearance
Later from PainChek
- 2nd peer-review confirms excellent performance of PainChek
- New Peer reviewed published study
- PainChek App Android version now in beta testing
- Half Year Report and Financial Statements
- Agreement signed with leading software system provider
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek